Dramatic response to SIRT, page-7

'Remember the Russian cohort for the ACL trial? Anyone? '

I think the quality of SRX trial to ACL is rather like chalk and cheese. There is somewhat of a difference with a large trial over many years primarily in the US, and one that was deliberately carried out in 2nd world (maybe 3rd world) centres due to the fact that they did not wish to meet the criteria in the US and Europe.

As one who invested in ACL I'm not happy, but I did understand the risks, and took some flack on HC when I tried to raise the quality of trials generally in 2nd tier centres

In any case I do hope you are right with your call of $1bn revenue. IMO about 6 years of 50%growth to get to that magic number. If the 2017 data shows good overall survival then just maybe they will in about 2020/2 Maybe a SP ~ 10 times current if and when they get there.